Abstract The Bioanalytical Core is a continuation of the shared resources offered in Phase-2 COBRE on Dietary Supplements and Inflammation (CDSI). The purpose of this Core is to assist and provide Pilot Project Faculty and other researchers associated or otherwise with the CDSI with cutting-edge and cost-effective methods of epigenetic and microbiome analysis that would lead to innovative and high-quality research. This Core specializes in designing and performing innovative –omics (scRNASeq and ATACSeq) research. Services provided by the Core in this area will include 1) Use of microarray-based approaches and bioinformatics tools for analysis of microRNA, mRNA and lncRNA expression data as well as performing pathway analysis 2) Performance of next generation sequencing-based assays such as ChIPSeq, MeDIPSeq, and RNASeq as well as 16S rRNA and shotgun sequencing to determine the effects of natural products on the genome, epigenome and microbiome, followed by data validation. 3) Screening and identification of natural product library for anti- inflammatory properties as well as analysis of receptor-ligand interactions. Thus, this Core will provide COBRE investigators with in-depth and complex analyses using specialized bioinformatics tools and statistical approaches to address the mechanistic effects of natural products on inflammation. With the advent of –omics technology that has resulted in the acquisition of big data, specialized technology and expertise are required for analyses that are usually not found in individual laboratories. The Core will also provide services in structural determination and binding analysis of natural compounds of interest to the CDSI and in understanding how botanicals promote the genomic, epigenomic, transcriptomic and microbiome regulation of inflammation. The Core will use an array of in silico analysis tools to determine natural compound structure and binding properties, which will provide insights into not only the physical properties of these compounds but also significant information pertaining to their functions as they bind and interact with various receptors. Results from these studies will be validated with biochemical assays meant to determine how these compounds can modulate the immune response. This Core is highly innovative and provides analytical tools that would lead to the identification of novel modes of action of botanicals and targets of inflammation. This would aid CDSI to develop new opportunities to pursue and advance inflammation research thereby promoting sustainability, a key component of COBRE Phase-3. In summary, this Core will serve as a state-of-the-art hub for the pursuit of cutting-edge research that should shed light on mechanisms of inflammation, including the identification of biomarkers for diagnosis and prognosis as well as new drug discovery against inflammatory diseases.